Article Text

Download PDFPDF
Randomised controlled trial
In TIA or stroke patients with intracranial arterial stenosis, aggressive medical therapy was superior to percutaneous transluminal angioplasty and stenting for 30-day risk of further stroke or death
  1. Tim Darsaut1,
  2. Jean Raymond1,
  3. Sylvain Lanthier2
  1. 1Department of Radiology, CHUM, Montreal, Canada
  2. 2Department of Medicine/Neurology, CHUM, Montreal, Canada
  1. Correspondence to Sylvain Lanthier
    Department of Medicine/Neurology, Centre hospitalier de l'Université de Montréal, 1560 East Sherbrooke Str. GR-1159, Montreal, Quebec, H2L4M1, Canada; sylanthier{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science


Patients with a recent transient ischaemic attack (TIA) or ischaemic stroke attributed to 70–99% intracranial artery stenosis have a 23% of 1-year risk for subsequent stroke. Over the past decade, intracranial angioplasty and stenting (IAS) has increasingly been used, without convincing evidence of efficacy or rigorous assessment of safety. Stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis (SAMMPRIS) was a clinical trial that sought to determine whether IAS combined with intensive medical management (IMM) was superior to IMM alone in the prevention of stroke and death.


Subjects were adults with 30–80 years of age, and had suffered a TIA or non-disabling stroke within 30 days of enrolment, attributed to an intracranial stenosis of 70–99% as documented …

View Full Text


  • Competing interests None.